Researchers Identified Breast Cancer Resistance Driver
A study found that the enzyme FAH contributes to treatment resistance in hormone receptor positive breast cancer.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Does the discovery of new cancer resistance mechanisms give you more hope for future treatments?
Boston Children's Hospital researchers discovered that the enzyme FAH enters the nucleus of breast cancer cells following treatment with CDK4/6 inhibitors. This process stimulates the activity of the regulator CDK9, which leads to cancer cell regrowth.
Why it matters
Patients currently treated with CDK4/6 inhibitors often develop resistance to the medication, causing their cancer to return. Identifying this specific mechanism provides a potential new pathway to stop relapse by inhibiting the CDK9 enzyme.
Researchers at Boston Children's Hospital identified FAH as a metabolic enzyme that functions in the nucleus after CDK4/6 inhibitor treatment. This nuclear presence acts as a regulator for CDK9 activity within the cancer cells.
The players
Boston Children's Hospital
This pediatric academic medical center conducts extensive biomedical research and is a teaching hospital for Harvard Medical School.
Science Advances
This is a peer-reviewed, open-access scientific journal published by the American Association for the Advancement of Science.
The details
The research, published in Science Advances, demonstrates how FAH interacts with the cell fate regulator CDK9 to support tumor survival. By blocking CDK9, investigators believe they can prevent the resistance mechanism that allows breast cancer to regenerate.
Timeline
September 30, 2026: Research findings were published in Science Advances.
The Big Picture
This study follows a pattern set by the development of CDK4/6 inhibitors for breast cancer treatment by identifying the specific biological pathways that cause these therapies to eventually lose effectiveness.
This research suggests that future breast cancer treatments could eventually include CDK9 inhibitors to improve long-term outcomes for patients on CDK4/6 therapy. Patients should consult their oncologists regarding how current resistance research might influence their specific care plans.
The takeaway
Understanding how cancer cells adapt to therapy is essential for developing next-generation treatments that prevent disease recurrence. Patients and their medical teams should stay informed about emerging biomarkers that may signal when a current treatment is becoming less effective.
Further reading
For more information on current treatment challenges, visit the Cancer section.
Live Poll
Does the discovery of new cancer resistance mechanisms give you more hope for future treatments?
